Cytogenetics of mantle cell lymphoma
- 作者: Obukhova TN1, Lorie Y.Y.1, Vodinskaya LA1, Alimova GA1, Nikitin EA1, Samoilova RS1, Kaplanskaya IВ1, Domracheva EV1
-
隶属关系:
- 期: 卷 79, 编号 7 (2004)
- 页面: 70-77
- 栏目: Editorial
- ##submission.dateSubmitted##: 09.04.2020
- ##submission.datePublished##: 15.07.2004
- URL: https://ter-arkhiv.ru/0040-3660/article/view/29999
- ID: 29999
如何引用文章
全文:
详细
Aim. To determine the type and rate of secondary chromosomal aberrations and role in pathogenesis of mantle cell lymphoma (MCL).
Material and methods. Standard cytogenetic examination (SCE) and fluorescent in situ hybridization (FISH) with tests for Uq22/ATM, 13ql4, 17pl3/p53, 9p 21/p 16 and chromosome 12 centromere were made in 28 patients.
Results. Secondary chromosomal aberrations were detected in 22 patients. Chromosomal abnormalities occurring in more than 2 cases include deletions 6ql5-q23 (53% cases); 1Ц22/АТМ (50%); 9p21 (36%, in half the cases deletion 9p21 was biallele); 13ql4 (32%); trisomy 3/3q, monosomy 20 and deletions/translocations Iq and Ip (27% and 20%) and deletion 17pl3/p53 (18%). Trisomies 12/12q, 6 and 18/18q, monosomies 2 and 16, deletions/translocations 2p and 16p were found in 2 cases each. The FISH technique identified 9 chromosomal anomalies missed at SCE. Deletions 6ql5q23 were seen in patients with privalent lesions of lymph nodes. Deletions llq, 13ql4, 9p21 and 17pl3 occur more frequently in transformation and the blastoid variant. Monosomy 20 was found only in patients with large cell transformations. This was the only cytogenetic defect characteristic for transformed cases, in contrast to denovoblastoid ones. Thus, deletions 6q, Uq23, 13ql4 and 9p21 are typical for MCL. Deletions 9p2I and 17pl3 are more characteristic for large cell variants of the tumor. Deletion 17pl3 occurs at the terminal stage of the disease in rapidly growing tumor mass and resistance to chemotherapy. FISH technique is effective in detection of submicroscopic rearrangements especially small deletions. No significant differences were found between transformed and de novo blastoid cases. This shows that the blastoid variant is not a specific biological form, it is rather a less typical manifestation of the disease due to some preclinical cytogenetic disorders.
Conclusion. Progression and transformation of MCL are related to mutation of proapoptotic genes and genes proteins of which are inhibitors of active complexes of Dl cycline. Specification of these mechanisms requires further investigations in patients with different clinicomorphological forms of the disease at various stages of the disease.
Material and methods. Standard cytogenetic examination (SCE) and fluorescent in situ hybridization (FISH) with tests for Uq22/ATM, 13ql4, 17pl3/p53, 9p 21/p 16 and chromosome 12 centromere were made in 28 patients.
Results. Secondary chromosomal aberrations were detected in 22 patients. Chromosomal abnormalities occurring in more than 2 cases include deletions 6ql5-q23 (53% cases); 1Ц22/АТМ (50%); 9p21 (36%, in half the cases deletion 9p21 was biallele); 13ql4 (32%); trisomy 3/3q, monosomy 20 and deletions/translocations Iq and Ip (27% and 20%) and deletion 17pl3/p53 (18%). Trisomies 12/12q, 6 and 18/18q, monosomies 2 and 16, deletions/translocations 2p and 16p were found in 2 cases each. The FISH technique identified 9 chromosomal anomalies missed at SCE. Deletions 6ql5q23 were seen in patients with privalent lesions of lymph nodes. Deletions llq, 13ql4, 9p21 and 17pl3 occur more frequently in transformation and the blastoid variant. Monosomy 20 was found only in patients with large cell transformations. This was the only cytogenetic defect characteristic for transformed cases, in contrast to denovoblastoid ones. Thus, deletions 6q, Uq23, 13ql4 and 9p21 are typical for MCL. Deletions 9p2I and 17pl3 are more characteristic for large cell variants of the tumor. Deletion 17pl3 occurs at the terminal stage of the disease in rapidly growing tumor mass and resistance to chemotherapy. FISH technique is effective in detection of submicroscopic rearrangements especially small deletions. No significant differences were found between transformed and de novo blastoid cases. This shows that the blastoid variant is not a specific biological form, it is rather a less typical manifestation of the disease due to some preclinical cytogenetic disorders.
Conclusion. Progression and transformation of MCL are related to mutation of proapoptotic genes and genes proteins of which are inhibitors of active complexes of Dl cycline. Specification of these mechanisms requires further investigations in patients with different clinicomorphological forms of the disease at various stages of the disease.
参考
- Воробьев А. И. Руководство по гематологии. М.: Ньюдиамед; 2003; т. 2: 85-90.
- Воробьев А. И., Кременецкая А. М., Лорие Ю. Ю. и др. Старые и новые опухоли лимфатической системы. Тер. арх 2000;7:9-13.
- Delmer A., Ajchenbaum-Cymbalista F., Tang R. et al. Over-expression of cyclin Dl in chronic B-cell malignancies with abnormality of chromosome llql3. Br. J. Haematol. 1995; 89' 798-804.
- Sherr С. J., Roberts J. M. CDK inhibitors: positive and negative regulators of Gl-phase progression. Genes Dev. 1999- 131501-
- Ott M. M., Bartkova J., Bartek J. et al. Cyclin Dl expression in mantle cell lymphoma is accompanied by downregulation of Cyclin D3 and is not related to the proliferative activity. Blood 1997; 90: 3154-3159.
- Brito-Babapulle V., Ellis J., Matutes E. et al. Chromosome translocation (Il;14)(ql3:q32) in chronic lymphoid disorders. Genes Chromosom. Cancer 1992; 5: 158-165.
- Fonseca R., Blood E. A., Oken M. M. et al. Myeloma and the t(ll;14) (ql3;q32); evidence for a biologically defined unique subset of patients. Blood 2002; 99: 3735-3741.
- Oscier D. G. Cytogenetics and molecular genetics of chronic lymphocytic leukemia. Haematologica 1999; 84: 88-91.
- Jaffe E. S., Harris N. I., Stein В., Vardiman J. W., eds. World Health Organization Classication of Tumours: Pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
- Sola В., Salaun V., Ballet J. J. et al. Transcriptional and posttranscriptional mechanisms induce Cyclin-Dl overexpression in B-chronic lymphoproliferative disorders. Int. J. Cancer 1999; 83: 230-234.
- Bertoni F. Molecular basis of mantle cell lymphoma. Br. J. Haematol. 2004; 124: 130-140.
- Bentz M., Plesch A., Bullinger L. et al. t(l 1; 14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia. Genes Chromosom. Cancer 2000; 27: 285-294.
- Bodrug S., Warner В., Bath M. et al. Cyclin Dl transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J. 1994; 13: 2124-2130.
- Harnden D. G., Klinger H. P., eds. An international system for human cytogenetic nomenclature. New York: ISCN; 1985.
- Wlodarska I., Pittaluga S., Hagemeijer A. et al. Secondary chromosome changes in mantle cell lymphoma. Haematologica 1999; 84: 594-599.
- Cuneo A., Bigoni R., Rigolin G. M. et al. Cytogenetic profile of lymphoma of follicle mantle lineage: correlation with clinicobiologic features. Blood 1999, 93: 1372-1380.
- Pittaluga S., Wlodarska I., Stul M. S. et al. Mantle cell lymphoma: A clinicopathologic study of 55 cases. Histopathology 1995; 26: 17-21.
- Tilly H., Rossi A., Stamatoullas A. et al. Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood 1994; 84: 1043-1049.
- Larramendy M. L., Siitonen S. M., Zhu Y. et al. Optimized mitogen stimulation induces proliferation of neoplastic B-cell in chronic lymphocytic leukemia: significance for cytogenetic analysis. Cytogenet. Cell Genet. 1998; 82: 215-221.
- Gaidano G., Hauptschein R. S., Parsa N. Z. et al. Deletions involving two distinct regions of 6q in B-cell non-Hodgkin's lymphoma. Blood 1992; 80: 1781-1787.
- Offit K., Parsa N. Z., Gaidano G. et al. 6q deletions define distinct clinico-pathologic subsets of non-Hodgkin's lymphoma. Blood 1993; 82: 2157-2162.
- Hayashi Y., Raimondi S. C., Look A. T. et al. Abnormalities of the long arm of chromosome 6 in childhood acute lymphoblastic leukemia. Blood 1990; 76: 1626-1630.
- Bigoni R., Cuneo A., Milani R. et al. Secondary chromosome changes in mantle cell lymphoma: cytogenetic and fluorescence in situ hybridization studies. Leukemia and Lymphoma 2001; 40(5-6): 581-590.
- Monni O., Oinonen R., Elonen E. et al. Gain of 3q and deletion of llq22 are frequent aberrations in mantle cell lymphoma. Genes Chromosom. Cancer 1998; 21: 298-302.
- Stilgenbauer S., Bullinger L., Benner A. et al. Incidence and clinical significance of 6q deletions in B-cell chronic lymphocytic leukemia. Leukemia 1999; 13: 1331-1334.
- Fang N. Y., Greiner T. C., Weisenburger D. D. et al. Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma. Proc Natl. Acad. Sci. USA 2003; 100: 5372-5377.
- Zhu Y., Monni O., Francilla K. et al. Deletions at llq23 in different lymphoma subtypes. Haematololgica 2000; 85: 908- 912.
- Stilgenbauer S., Winkler D., Ott G. et al. Molecular Characterization of llq Deletions Points to a Pathogenic Role of the ATM Gene in Mantle Cell Lymphoma. Blood 1999; 943262-3264.
- Stankovic T., Weber P., Stewart G. et al. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet 1999; 353: 26-30.
- Schaffner C., Stilgenbauer S., Rappold G. et al. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell lymphocytic leukemia. Blood 1999; 94: 748-753.
- Camacho F. I., Algara P., Rodriguez A. et al. Molecular heterogeneity in MCL, defined by the use of specific VH genes and the frequency of somatic mutations. Blood 2003; 101: 4042- 4046.
- Bullrich F., Rasio D., Kitada S. et al. ATM Mutations in BCell Chronic Lymphocytic Leukemia. Cancer Res. 1999; 59: 24-32.
- Levine A. J. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
- Doner H., Stilgenbauer S., Benner A. et al. Genomic aberration and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 2000; 343: 1910-1916.
- Arcinas M., Heckman С. A., Mehew J. W. et al. Molecular mechanisms of transcriptional control of bcl-2 and c-myc in follicular and transformed lymphoma. Cancer Res. 2001; 61: 5202-5206.
- Au W. Y., Horsman D. E., Viswanatha D. S. 8q24 translocations in blastic transformation of mantle cell lymphoma. Haematologica 2000; 85: 1225-1226.
- Tirier C., Zhang Y., Plendl H. et al. Simultaneous presence of t(ll; 14) and a variant Burkitt's translocation in the terminal phase of a mantle cell lymphoma. Leukemia 1996; 10: 346- 350.
补充文件
![](/img/style/loading.gif)